Company profile
Ovation Science Inc.
OTC: OVATF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#1083 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
23DFH 20DQ —GM 32SS 26
v0.1 · 45/100 weight · provisional
↑ disclosure history, growth stability · ↓ balance-sheet leverage, return on assets
Methodology →Revenue TTM
$41.5k
Rev growth YoY (TTM)
-10.5%
Net income (FY)
-$451.2k
Employees
5
as of 2026-08-25
Market cap
$288.3k
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$48.5k67.8k CAD2025
Net income-$451.2k-630.7k CAD2025
Operating income-$427.6k-597.7k CAD2025
Total assets$60.4k82.8k CAD2025
Liabilities$1.1M1.5M CAD2025
Equity-$1.1M-1.5M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Ovation Science Inc.’s revenue?
Ovation Science Inc. booked $48.5k in FY2025 revenue, contracting 41% year over year — slower than 79% of Healthcare companies we track, at a -929.9% net margin.
Peers · Healthcare
Natural Health Farm Holdings Inc.——INmune Bio, Inc.41DMultiCell Technologies, Inc.——DIAGNOS Inc.29DCalidi Biotherapeutics, Inc.19DMillennium Sustainable Ventures Corp.——Key facts
CEOTerry H. Howlett
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: OVATF
Employees5
IPO date2019-01-29
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.